PIM
STOK icon

Platinum Investment Management’s Stoke Therapeutics STOK Stock Holding History

Platinum Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Hold
40,815
– – 0.34% 73
2025
Q4 		$1.3M Buy
40,815
+7,914
+24% +$238K 0.3% 79
2025
Q3 		$773K Buy
+32,901
New +$564K 0.05% 90
2019
Q4 		– Sell
-1,000
Closed -$21K – 103
2019
Q3 		$21K Hold
1,000
– – ﹤0.01% 99
2019
Q2 		$29K Buy
+1,000
New +$26.9K ﹤0.01% 97

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Platinum Investment Management's STOK Position: Q1 2026 in Review

Platinum Investment Management held its Stoke Therapeutics (STOK) position steady in Q1 2026 at 40,815 shares worth $1.33M. The position accounts for 0.34% of the portfolio, ranked #73.

Platinum Investment Management first reported a position in STOK in Q2 2019 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Platinum Investment Management held 40,815 shares of Stoke Therapeutics worth $1.33M as of Q1 2026.
  • Platinum Investment Management left its Stoke Therapeutics share count unchanged in Q1 2026.
  • Stoke Therapeutics made up 0.34% of Platinum Investment Management's portfolio in Q1 2026, its #73 holding.
  • Platinum Investment Management first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Platinum Investment Management's 13F filing for Q1 2026, filed 14 May 2026.